- BetterLife (BETR) closes $6.325 million bought deal public offering of units, including full exercise of the over-allotment option
- Each unit consists of one common share in the capital of Betterlife and one common share purchase warrant of BetterLife
- The offering was led by Research Capital Corporation
- BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next-generation psychedelic products
- BetterLife Pharma Inc. (BETR) is trading at C$0.39.
BetterLife Pharma Inc. (BETR) has closed its bought-deal public offering.
BetterLife issued 15.8 million units at a price of $0.40 per unit for aggregate gross proceeds of $6,325,000, including the full exercise of the over-allotment option.
Each unit consists of one common share in the capital of Betterlife and one common share purchase warrant of BetterLife.
Each warrant entitles the holder thereof to purchase one common share at an exercise price of $0.50 at any time up to 36 months from the closing of the offering.
The offering was led by Research Capital Corporation as the sole underwriter and sole bookrunner.
BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next-generation psychedelic products for the treatment of mental disorders.
BetterLife Pharma Inc. (BETR) is trading at C$0.39.
